Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Open Monoclonal Technology
Builds the first platform for generating human monoclonal antibodies using a transgenic rat
Palo Alto, CA
Contact:
Ron Eastman
Acquired by: Ligand Pharmaceuticals
Exit date: December 11, 2015
Related News
Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash & Stock
Open Monoclonal Technology Announces OmniAb Alliance with Amgen
OMT Therapeutics Announces UniRat Alliance with Caltech
Open Monoclonal Technology Announces OmniAb Alliance with Celgene
Open Monoclonal Technology Provides Important Intellectual Property Update
Roche and Genentech Acquire Unlimited Access to Open Monoclonal Technology’s OmniRat®
Symphogen and Open Monoclonal Technology Announce Collaboration
OMT Grants Unlimited Platform Access to CNA Development LLC
Open Monoclonal Technology Looks to Sell Subsidiaries
WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat™ Antibody Collaboration
‘Rat” Gain: OMT Developing Alternative to Mouse mAbs
OMT Announces New Antibody Discovery Program
Cambridge Healthtech Associates™ Announces Open Monoclonal Technology as Inaugural Signature Award™
OMT Announces Novel Human Antibody Platfordm
Developing Knockout Rats for Antibody Discovery
